P021. In-house in-situ hybridisation accelerates indeterminate HER2 lesion results

Introduction: NICE guidelines 1.6.5 recommend: 'that the HER2 status [should be] available and recorded at the pre-operative multidisciplinary team (MDT) meeting when systemic treatment is discussed' to optimise decision-making regarding neoadjuvant therapy. Indeterminate HER2 lesions, however, require further testing by in-situ hybridisation (ISH). This may lead to delays in treatment decision-making, particularly if the testing is outsourced....